Heparin-Induced Thrombocytopenia in Intensive Care Patients

 

 Buy Article Permissions and Reprints

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a serious, prothrombotic, immune-mediated complication of heparin therapy that can cause limb- and life-threatening thromboembolic events. Prompt diagnosis and therapeutic dose anticoagulation by an alternative anticoagulant are crucial to improve clinical outcome. In critically ill patients, the diagnosis of HIT is difficult due to the high incidence of thrombocytopenia, often caused by reasons other than HIT, and the high incidence of clinically irrelevant, non-platelet-activating anti–PF4-heparin antibodies. Also, treatment of HIT is problematic in these patients. No antidote is available for any of the alternative anticoagulants, and their half-lives are often prolonged in the presence of renal or hepatic insufficiency. This increases the risk of bleeding complications and mandates careful balancing of both risks, thrombosis and bleeding. Therefore, accurate diagnosis of HIT and individual choice of alternative anticoagulant are important for the adequate management of critically ill HIT patients.

REFERENCES

• 1 Visentin G P, Liu C Y, Aster R H. Molecular immunopathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 149-166
  Google Scholar
• 2 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126 311S-337S
  CrossrefPubMedGoogle Scholar
• 3 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 21-66
  Google Scholar
• 4 Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent J L. Time course of platelet counts in critically ill patients.  Crit Care Med. 2002;  30 753-756
  CrossrefPubMedGoogle Scholar
• 5 Crowther M A, Cook D J, Meade M O et al.. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors.  J Crit Care. 2005;  20 348-353
  CrossrefPubMedGoogle Scholar
• 6 Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn E G. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome.  Crit Care Med. 2002;  30 1765-1771
  CrossrefPubMedGoogle Scholar
• 7 Warkentin T E, Roberts R S, Hirsh J, Kelton J G. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients.  Arch Intern Med. 2003;  163 2518-2524
  CrossrefPubMedGoogle Scholar
• 8 Pouplard C, May M A, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies.  Br J Haematol. 2005;  128 837-841
  CrossrefPubMedGoogle Scholar
• 9 Selleng S, Selleng K, Wollert H G et al.. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass.  J Thromb Haemost. 2008;  6 428-435
  CrossrefPubMedGoogle Scholar
• 10 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review.  Semin Thromb Hemost. 2006;  32 803-809
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.  Blood. 2000;  96 846-851
  CrossrefPubMedGoogle Scholar
• 12 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: towards consensus.  Thromb Haemost. 1998;  79 1-7
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3.  J Thromb Haemost. 2005;  3 2428-2436
  CrossrefPubMedGoogle Scholar
• 14 Warkentin T E, Kelton J G. A 14-year study of heparin-induced thrombocytopenia.  Am J Med. 1996;  101 502-507
  CrossrefPubMedGoogle Scholar
• 15 Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin T E, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.  Thromb Haemost. 2005;  94 132-135
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Warkentin T E, Greinacher A. Thrombosis of the cerebral veins and sinuses.  N Engl J Med. 2005;  353 314-315
  CrossrefPubMedGoogle Scholar
• 17 Wester J P, Haas F J, Biesma D H, Leusink J A, Veth G. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients.  Intensive Care Med. 2004;  30 1927-1934
  CrossrefPubMedGoogle Scholar
• 18 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.  Thromb Haemost. 1994;  71 247-251
  CrossrefPubMedGoogle Scholar
• 20 Greinacher A, Gopinadhan M, Gunther J U et al.. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.  Arterioscler Thromb Vasc Biol. 2006;  26 2386-2393
  CrossrefPubMedGoogle Scholar
• 21 Rauova L, Poncz M, McKenzie S E et al.. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.  Blood. 2005;  105 131-138
  CrossrefPubMedGoogle Scholar
• 22 Rauova L, Zhai L, Kowalska M A, Arepally G M, Cines D B, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.  Blood. 2006;  107 2346-2353
  CrossrefPubMedGoogle Scholar
• 23 Warkentin T E, Cook R J, Marder V J et al.. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.  Blood. 2005;  106 3791-3796
  CrossrefPubMedGoogle Scholar
• 24 Denomme G A. Platelet and leukocyte Fcγ receptors in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 187-208
  Google Scholar
• 25 Warkentin T E. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.  Transfus Med Rev. 1996;  10 249-258
  PubMedGoogle Scholar
• 26 Arepally G M, Poncz M, Cines D B. Immune vascular injury in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 209-225
  Google Scholar
• 27 Warkentin T E. Heparin-induced thrombocytopenia: a clinicopathologic syndrome.  Thromb Haemost. 1999;  82 439-447
  PubMedGoogle Scholar
• 28 Warkentin T E, Sheppard J A, Moore J C, Moore K M, Sigouin C S, Kelton J G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?.  J Lab Clin Med. 2005;  146 341-346
  CrossrefPubMedGoogle Scholar
• 29 Warkentin T E, Sheppard J A. Testing for heparin-induced thrombocytopenia antibodies.  Transfus Med Rev. 2006;  20 259-272
  CrossrefPubMedGoogle Scholar
• 30 Warkentin T E, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 227-260
  Google Scholar
• 31 Prechel M, Walenga J M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.  Semin Thromb Hemost. 2008;  34 86-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 32 Greinacher A, Juhl D, Strobel U et al.. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.  J Thromb Haemost. 2007;  5 1666-1673
  CrossrefPubMedGoogle Scholar
• 33 Lo G K, Sigouin C S, Warkentin T E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?.  Am J Hematol. 2007;  82 1037-1043
  CrossrefPubMedGoogle Scholar
• 34 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
  CrossrefPubMedGoogle Scholar
• 35 Greinacher A, Warkentin T E. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 283-317
  Google Scholar
• 36 Lee D H, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 67-116
  Google Scholar
• 37 Martel N, Lee J, Wells P S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis.  Blood. 2005;  106 2710-2715
  CrossrefPubMedGoogle Scholar
• 38 Warkentin T E, Sheppard J A, Sigouin C S, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia.  Blood. 2006;  108 2937-2941
  CrossrefPubMedGoogle Scholar
• 39 Pohl C, Kredteck A, Bastians B, Hanfland P, Klockgether T, Harbrecht U. Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin.  Neurology. 2005;  64 1285-1287
  CrossrefPubMedGoogle Scholar
• 40 Lindhoff-Last E, Nakov R, Misselwitz F, Breddin H K, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.  Br J Haematol. 2002;  118 1137-1142
  CrossrefPubMedGoogle Scholar
• 41 Morris T A, Castrejon S, Devendra G, Gamst A C. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.  Chest. 2007;  132 1131-1139
  CrossrefPubMedGoogle Scholar
• 42 Schenk S, El Banayosy A, Prohaska W et al.. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support.  J Thorac Cardiovasc Surg. 2006;  131 1373-1381
  CrossrefPubMedGoogle Scholar
• 43 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med. 1995;  332 1330-1335
  CrossrefPubMedGoogle Scholar
• 44 Greinacher A, Eichler P, Lietz T, Warkentin T E. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia.  Blood. 2005;  106 2921-2922
  CrossrefPubMedGoogle Scholar
• 45 Verma A K, Levine M, Shalansky S J, Carter C J, Kelton J G. Frequency of heparin-induced thrombocytopenia in critical care patients.  Pharmacotherapy. 2003;  23 745-753
  CrossrefPubMedGoogle Scholar
• 46 Cook D, Crowther M, Meade M et al.. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors.  Crit Care Med. 2005;  33 1565-1571
  CrossrefPubMedGoogle Scholar
• 47 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery.  Ann Thorac Surg. 2003;  76 2121-2131
  CrossrefPubMedGoogle Scholar
• 48 Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).  Thromb Haemost. 2008;  99 779-781
  PubMedGoogle Scholar
• 49 Warkentin T E, Maurer B T, Aster R H. Heparin-induced thrombocytopenia associated with fondaparinux.  N Engl J Med. 2007;  356 2653-2655
  CrossrefPubMedGoogle Scholar
• 50 Bartholomew J R. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 379-408
  Google Scholar
• 51 Greinacher A. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.  Expert Rev Cardiovasc Ther. 2004;  2 339-357
  CrossrefPubMedGoogle Scholar
• 52 Lindhoff-Last E, Piechottka G P, Rabe F, Bauersachs R. Hirudin determination in plasma can be strongly influenced by the prothrombin level.  Thromb Res. 2000;  100 55-60
  CrossrefPubMedGoogle Scholar
• 53 Lange U, Nowak G, Bucha E. Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin.  Pathophysiol Haemost Thromb. 2003;  33 184-191
  CrossrefPubMedGoogle Scholar
• 54 Warkentin T E, Greinacher A, Craven S, Dewar L, Sheppard J A, Ofosu F A. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.  Thromb Haemost. 2005;  94 958-964
  PubMedGoogle Scholar
• 55 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104 3072-3077
  CrossrefPubMedGoogle Scholar
• 56 Tardy B, Lecompte T, Boelhen F et al.. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.  Blood. 2006;  108 1492-1496
  CrossrefPubMedGoogle Scholar
• 57 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108 2062-2065
  CrossrefPubMedGoogle Scholar
• 58 Greinacher A, Warkentin T E. The direct thrombin inhibitor hirudin.  Thromb Haemost. 2008;  99 819-829
  PubMedGoogle Scholar
• 59 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
  CrossrefPubMedGoogle Scholar
• 60 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
  CrossrefPubMedGoogle Scholar
• 61 Lewis B E, Wallis D E, Hursting M J, Levine R L, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.  Chest. 2006;  129 1407-1416
  CrossrefPubMedGoogle Scholar
• 62 Lewis B E, Hursting M J. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 379-408
  Google Scholar
• 63 Kiser T H, Jung R, MacLaren R, Fish D N. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.  Pharmacotherapy. 2005;  25 1736-1745
  CrossrefPubMedGoogle Scholar
• 64 Beiderlinden M, Treschan T A, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients.  Ann Pharmacother. 2007;  41 749-754
  CrossrefPubMedGoogle Scholar
• 65 Kodityal S, Nguyen P H, Kodityal A, Sherer J, Hursting M J, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital.  J Intensive Care Med. 2006;  21 86-92
  CrossrefPubMedGoogle Scholar
• 66 Hoffman W D, Czyz Y, McCollum D A, Hursting M J. Reduced argatroban doses after coronary artery bypass graft surgery.  Ann Pharmacother. 2008;  42 309-316
  CrossrefPubMedGoogle Scholar
• 67 Warkentin T E, Greinacher A, Koster A. Bivalirudin.  Thromb Haemost. 2008;  99 830-839
  PubMedGoogle Scholar
• 68 Mann M J, Tseng E, Ratcliffe M et al.. Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.  J Heart Lung Transplant. 2005;  24 222-225
  CrossrefPubMedGoogle Scholar
• 69 Kiser T H, Fish D N. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.  Pharmacotherapy. 2006;  26 452-460
  CrossrefPubMedGoogle Scholar
• 70 Chong B H, Gallus A S, Cade J F et al.. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.  Thromb Haemost. 2001;  86 1170-1175
  PubMedGoogle Scholar
• 71 Chong B H, Magnani H N. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 295-318
  Google Scholar
• 72 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
  Article in Thieme ConnectPubMedGoogle Scholar
• 73 Lubenow N, Warkentin T E, Greinacher A et al.. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.  Thromb Res. 2006;  117 507-515
  CrossrefPubMedGoogle Scholar
• 74 Tardy-Poncet B, Tardy B, Reynaud J et al.. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.  Chest. 1999;  115 1616-1620
  CrossrefPubMedGoogle Scholar
• 75 Efird L E, Kockler D R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.  Ann Pharmacother. 2006;  40 1383-1387
  CrossrefPubMedGoogle Scholar
• 76 Lobo B L. Use of newer anticoagulants in patients with chronic kidney disease.  Am J Health Syst Pharm. 2007;  64 2017-2026
  CrossrefPubMedGoogle Scholar
• 77 Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.  Clin Pharmacol Ther. 2002;  71 433-439
  PubMedGoogle Scholar
• 78 Fischer K G. Hirudin in renal insufficiency.  Semin Thromb Hemost. 2002;  28 467-482
  Article in Thieme ConnectPubMedGoogle Scholar
• 79 Frank R D, Farber H, Stefanidis I, Lanzmich R, Kierdorf H P. Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes.  Kidney Int Suppl. 1999;  72 S41-S45
  PubMedGoogle Scholar
• 80 Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.  Thromb Res. 2001;  101 145-157
  PubMedGoogle Scholar
• 81 Ibbotson S H, Grant P J, Kerry R, Findlay V S, Prentice C R. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.  Thromb Haemost. 1991;  65 64-66
  PubMedGoogle Scholar
• 82 Yee A J, Kuter D J. Successful recovery after an overdose of argatroban.  Ann Pharmacother. 2006;  40 336-339
  PubMedGoogle Scholar
• 83 Warkentin T E, Cook D J. Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU.  Crit Care Clin. 2005;  21 513-529
  CrossrefPubMedGoogle Scholar
• 84 Napolitano L M, Warkentin T E, Almahameed A, Nasraway S A. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management.  Crit Care Med. 2006;  34 2898-2911
  CrossrefPubMedGoogle Scholar
• 85 Huhle G, Geberth M, Hoffmann U, Heene D L, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.  Gynecol Obstet Invest. 2000;  49 67-69
  CrossrefPubMedGoogle Scholar
• 86 Eriksson B I, Wille-Jorgensen P, Kalebo P et al.. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337 1329-1335
  CrossrefPubMedGoogle Scholar
• 87 Eriksson B I. New therapeutic options in deep vein thrombosis prophylaxis.  Semin Hematol. 2000;  37 7-9
  PubMedGoogle Scholar
• 88 Fischer K-G. Hemodialysis in Heparin-Induced Thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Informa Healthcare 2007: 463-485
  Google Scholar
• 89 Murray P T, Reddy B V, Grossman E J et al.. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.  Kidney Int. 2004;  66 2446-2453
  CrossrefPubMedGoogle Scholar
• 90 de Pont A C, Hofstra J J, Pik D R, Meijers J C, Schultz M J. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.  Crit Care. 2007;  11 R102
  CrossrefPubMedGoogle Scholar
• 91 Tang I Y, Cox D S, Patel K et al.. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.  Ann Pharmacother. 2005;  39 231-236
  PubMedGoogle Scholar
• 92 Horne M K, McCloskey D J, Calis K, Wesley R, Childs R, Kasten-Sportes C. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices.  Pharmacotherapy. 2006;  26 1262-1267
  CrossrefPubMedGoogle Scholar

Prof. Dr. med. Andreas Greinacher

Institut für Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt Universität, Greifswald Sauerbruchstraße

D 17487 Greifswald, Germany

Email: greinach@uni-greifswald.de